PROM1 and lung adenocarcinoma: It was reported that pretreatment with ATRA can reverse cisplatin resistance, specifically of the slowly dividing compartment, indicating an effect on CD133+/CXCR4+ cells in lung adenocarcinoma patient-derived xenograft model.